Antiretroviral-experienced HIV-1-infected patients treated with maraviroc: Factors associated with virological response

AIDS Research and Human Retroviruses

Volumn 31, Issue 5, 2015, Pages 475-478

  Soulie, Cathia ^a,b,c   Peytavin, Gilles ^d,e   Charpentier, Charlotte ^d,e   Lambert Niclot, Sidonie ^a,b,c   Sayon, Sophie ^a,b,c   Visseaux, Benoit ^d,e   Simon, Anne ^c   Katlama, Christine ^a,b,c   Yazdanpanah, Yazdan ^d,e   Descamps, Diane ^d,e   Calvez, Vincent ^a,b,c   Marcelin, Anne Geneviève ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC; RALTEGRAVIR; VIRUS RNA; ANTIRETROVIRUS AGENT; CYCLOHEXANE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRAL PHENOMENA AND FUNCTIONS; VIRAL TROPISM; VIROLOGICAL RESPONSE; VIRUS LOAD; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CYCLOHEXANES; DRUG THERAPY, COMBINATION; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD; YOUNG ADULT;

EID: 84928950339     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0223     Document Type: Article

References (11)

1. Gulick RM, Lalezari J, Goodrich J, et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-1441.
2. Fatkenheuer G, Nelson M, Lazzarin A, et al.: Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359:1442-1455.
3. Cooper DA, Heera J, Goodrich J, et al.: Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010;201:803-813.
4. Recordon-Pinson P, Soulie C, Flandre P, et al.: Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: The ANRS GenoTropism study. Antimicrob Agents Chemother 2010;54:3335-3340.
5. Jung BH, Rezk NL, Bridges AS, et al.: Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007;21:1095-1104.
6. Stellbrink H-J, Szlavik J, Murphy D, et al.: Maraviroc (MVC) dosed once daily with darunavir/ritonavir (DRV/r) in a 2 drug-regimen compared to emtricitabine/tenofovir (TDF/FTC) with DRV/r; 48-week results from MODERN (Study A4001095). 20th International AIDS Conference. Melbourne, Australia, 2014.
7. Soulie C, Fourati S, Lambert-Niclot S, et al.: Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: Implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother 2010;65:749-751.
8. Dina J, Raymond S, Maillard A, et al.: Algorithm-based prediction of HIV-1 subtype D coreceptor use. J Clin Microbiol 2013;51:3087-3089.
9. Raymond S, Delobel P, Rogez S, et al.: Genotypic prediction of HIV-1 CRF01-AE tropism. J Clin Microbiol 2013;51:564-570.
10. Raymond S, Delobel P, Chaix ML, et al.: Genotypic prediction of HIV-1 subtype D tropism. Retrovirology 2011;8:56.
11. Raymond S, Delobel P, Mavigner M, et al.: Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol 2009;47:2292-2294.